Delving into the Latest Updates on ISA-201 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide vaccine, Therapeutic vaccine

Synonyms

Hespecta

+ [1]

Target

HPV E6

Action

inhibitors

Mechanism

HPV E6 inhibitors(HPV E6 inhibitors)

Therapeutic Areas

NeoplasmsInfectious Diseases

Active Indication

Head and Neck NeoplasmsHuman Papillomavirus Infection

Inactive Indication

Precancerous ConditionsVisible Lesion

Originator Organization

ISA Pharmaceuticals BV

Active Organization

ISA Pharmaceuticals BV

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV) and porcine deltacoronavirus (PDCoV) cause highly contagious gastrointestinal damage to piglets with high coinfection in clinical. However, there is no available trivalent vaccine against the three viruses. Here, a trivalent subunit vaccine by combining PEDV-S_COE, TGEV-S_AD, and PDCoV-RBD proteins with ISA 201 adjuvant was effectively prepared, and the immunogenicity was evaluated. The detection results showed that the vaccine induced specific humoral IgG, neutralizing antibodies, and increased levels of Th1 and Th2 cytokines. Splenocytes proliferation and specific cytotoxic T lymphocytes (CTL) were activated. Furthermore, the three antigenic proteins up-regulated CD4⁺ and CD8⁺ T lymphocytes, activated the germinal center (GC) through the Tfh-GC axis, and promoted the differentiation of GC B cells in to plasma cells and memory B cells. Overall, the three antigenic proteins will provide helpful information for further exploration of trivalent vaccines against PEDV, TGEV, and PDCoV.

31 Dec 2024·Emerging Microbes & Infections

A single immunization with H5N1 virus-like particle vaccine protects chickens against divergent H5N1 influenza viruses and vaccine efficacy is determined by adjuvant and dosage

Article

Author: Ao, Xiang ; Fan, Huiying ; Kong, Dexin ; Qiu, Weihong ; Ye, Hejia ; Liao, Ming ; Chi, Lanyan ; Zhu, Xiutong ; Wang, Jiaxin ; He, Yanjuan

The H5N1 subtype highly pathogenic avian influenza virus (HPAIV) reveals high variability and threatens poultry production and public health. To prevent the spread of H5N1 HPAIV, we developed an H5N1 virus-like particle (VLP) vaccine based on the insect cell-baculovirus expression system. Single immunization of the H5N1 VLP vaccines induced high levels of HI antibody titres and provided effective protection against homologous virus challenge comparable to the commercial inactivated vaccine. Meanwhile, we assessed the relative efﬁcacy of different adjuvants by carrying out a head-to-head comparison of the adjuvants ISA 201 and ISA 71 and evaluated whether the two adjuvants could induce broadly protective immunity. The ISA 71 adjuvanted vaccine induced significantly higher levels of Th1 and Th2 immune responses and provided superior cross-protection against antigenically divergent H5N1 virus challenge than the ISA 201 adjuvanted vaccine. Importantly, increasing the vaccine dose could further enhance the cross-protective efficacy of H5N1 VLP vaccine and confer completely sterilizing protection against antigenically divergent H5N1 virus challenge, which was mediated by neutralizing antibodies. Our results suggest that the H5N1 VLP vaccine can provide broad-spectrum protection against divergent H5N1 influenza viruses as determined by adjuvant and vaccine dose.

01 Oct 2024·Vaccine

Superior protection against paratuberculosis by a heterologous prime-boost immunization in a murine model

Article

Author: Cuerda, María Ximena ; de la Paz Santangelo, María ; Gravisaco, María José ; Moyano, Roberto Damián ; Pinedo, María Fiorella Alvarado ; Calamante, Gabriela ; Delgado, Fernando Oscar ; Del Medico Zajac, María Paula ; Mundo, Silvia ; Romano, María Isabel ; Alonso, María Natalia ; Colombatti Olivieri, María Alejandra

Vaccination is the best strategy to control Paratuberculosis (PTB), which is a significant disease in cattle and sheep. Previously we showed the humoral and cellular immune response induced by a novel vaccine candidate against PTB based on the Argentinian Mycobacterium avium subspecies paratuberculosis (Map) 6611 strain. To improve 6611 immunogenicity and efficacy, we evaluated this vaccine candidate in mice with two different adjuvants and a heterologous boost with a recombinant modified vaccinia Ankara virus (MVA) expressing the antigen 85A (MVA85A). We observed that boosting with MVA85A did not improve total IgG or specific isotypes in serum induced by one or two doses of 6611 formulated with incomplete Freund's adjuvant (IFA). However, when 6611 was formulated with ISA201 adjuvant, MVA85A boost enhanced the production of IFNγ, Th1/Th17 cytokines (IL-2, TNF, IL-17A) and IL-6, IL-4 and IL-10. Also, this group showed the highest levels of IgG2b and IgG3 isotypes, both important for better protection against Map infection in the murine model. Finally, the heterologous scheme elicited the highest levels of protection after Map challenge (lowest CFU count and liver lesion score). In conclusion, our results encourage further evaluation of 6611 strain + ISA201 prime and MVA85A boost in bovines.

100 Deals associated with ISA-201

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 2	-	ISA Pharmaceuticals BV	-
Human Papillomavirus Infection	Phase 2	-	ISA Pharmaceuticals BV	-
Precancerous Conditions	Discovery	Netherlands	ISA Pharmaceuticals BV	01 Mar 2015
Visible Lesion	Discovery	Netherlands	ISA Pharmaceuticals BV	01 Mar 2015